Skip to search formSkip to main contentSkip to account menu

CetuGEX

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.
59Background: Standard treatment for RM-HNSCC is a combination of cisplatin (P), 5-FU (F), and the epidermal growth factor… 
2018
2018
CetuGEX and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): PK/PD results from the phase II RESGEX study.
61Background: Standard treatment for RM-HNSCC is a combination of cisplatin (P), 5-FU (F), and the EGFR blocking monoclonal… 
2018
2018
The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.
TPS2596Background: TO (CetuGEX) is a second-generation anti-EGFR antibody that specifically binds to EGFR and acts as a… 
2016
2016
EGFRK 521 mediates resistance to Cetuximab in head and neck cancer
  • 2016
  • Corpus ID: 207765917
EGFRK521 mediates resistance to Cetuximab in head and neck cancer 1 Friederike Braig, Malte Kriegs, Minna Voigtlaender, Beate… 
2016
2016
Abstract B068: Hydrocortisone, prednisolone, methylprednisolone, and dexamethasone inhibit CetuGEX™-mediated ADCC in vitro
Introduction: Antibody dependent cellular cytotoxicity is a key mode of action of therapeutic antibodies. ADCC enhancement as… 
2013
2013
First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.
3008 Background: Epidermal growth factor receptor (EGFR) is a validated target in cancer. EGFR antagonists in clinical use do not… 
2013
2013
L03.03PHASE I CLINICAL AND PHARMACOLOGICAL STUDY OF CETUGEX, A NOVEL ANTI-EGFR MONOCLONAL ANTIBODY WITH AN OPTIMIZED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)